Atezolizumab plus bevacizumab as first-line systemic therapy for hepatocellular carcinoma: a multi-institutional cohort study Article Swipe
Michael H. Storandt
,
Tyler Zemla
,
Kanchi Patell
,
Nikolas Naleid
,
Jennifer Gile
,
Nguyen H. Tran
,
Sakti Chakrabarti
,
Zhaohui Jin
,
Mitesh J. Borad
,
Amit Mahipal
·
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1093/oncolo/oyae142
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1093/oncolo/oyae142
Background Atezolizumab plus bevacizumab is the standard of care for advanced hepatocellular carcinoma (HCC) in the first-line setting, although was only evaluated in patients with Child-Pugh (CP) A liver function in the IMbrave150 trial. We sought to determine the outcomes of these patients based on CP score and ALBI grade in the US population. Methods This multicenter cohort study included patients with HCC who received atezolizumab with bevacizumab as first-line systemic therapy between March 2018 and November 2023. Overall survival (OS) was determined using the Kaplan-Meier method and multivariate analyses were performed using Cox proportional hazard regression method. Results Among 322 patients, 226, 86, and 10 patients had CP-A, CP-B, and CP-C liver function, respectively. Median age was 66.5 years, 78.6% were male, and 82.6% were White. Median OS (mOS) was 21.6 months for those with CP-A, 9.1 months for those with CP-B7, and 4.7 months for those with CP-B8-C12 (P < .0001). Among patients with CP-A, those with ALBI grade 1 had an mOS of 34.9 months versus 14.2 months in those with grade 2. In multivariate analyses, CP score, ALBI grade, hepatitis B, performance status, and macrovascular invasion were significantly associated with survival. Conclusions CP score is an important prognostic tool for patients with HCC receiving atezolizumab plus bevacizumab, and this regimen remains a viable option for patients with CP-B7 with no additional safety concern, although the benefit is significantly less than those with CP-A. ALBI score has independent predictive value in patients with CP-A liver function.
Related Topics
Concepts
Medicine
Atezolizumab
Bevacizumab
Internal medicine
Hepatocellular carcinoma
Hazard ratio
Proportional hazards model
Cohort
Regimen
Liver function
Population
Gastroenterology
Propensity score matching
Oncology
Surgery
Cancer
Chemotherapy
Confidence interval
Immunotherapy
Pembrolizumab
Environmental health
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1093/oncolo/oyae142
- https://academic.oup.com/oncolo/advance-article-pdf/doi/10.1093/oncolo/oyae142/58482539/oyae142.pdf
- OA Status
- gold
- Cited By
- 15
- References
- 22
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4400457966
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4400457966Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1093/oncolo/oyae142Digital Object Identifier
- Title
-
Atezolizumab plus bevacizumab as first-line systemic therapy for hepatocellular carcinoma: a multi-institutional cohort studyWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2024Year of publication
- Publication date
-
2024-07-09Full publication date if available
- Authors
-
Michael H. Storandt, Tyler Zemla, Kanchi Patell, Nikolas Naleid, Jennifer Gile, Nguyen H. Tran, Sakti Chakrabarti, Zhaohui Jin, Mitesh J. Borad, Amit MahipalList of authors in order
- Landing page
-
https://doi.org/10.1093/oncolo/oyae142Publisher landing page
- PDF URL
-
https://academic.oup.com/oncolo/advance-article-pdf/doi/10.1093/oncolo/oyae142/58482539/oyae142.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://academic.oup.com/oncolo/advance-article-pdf/doi/10.1093/oncolo/oyae142/58482539/oyae142.pdfDirect OA link when available
- Concepts
-
Medicine, Atezolizumab, Bevacizumab, Internal medicine, Hepatocellular carcinoma, Hazard ratio, Proportional hazards model, Cohort, Regimen, Liver function, Population, Gastroenterology, Propensity score matching, Oncology, Surgery, Cancer, Chemotherapy, Confidence interval, Immunotherapy, Pembrolizumab, Environmental healthTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
15Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 14, 2024: 1Per-year citation counts (last 5 years)
- References (count)
-
22Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4400457966 |
|---|---|
| doi | https://doi.org/10.1093/oncolo/oyae142 |
| ids.doi | https://doi.org/10.1093/oncolo/oyae142 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/38979643 |
| ids.openalex | https://openalex.org/W4400457966 |
| fwci | 12.58553 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D006801 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Humans |
| mesh[1].qualifier_ui | Q000627 |
| mesh[1].descriptor_ui | D000068258 |
| mesh[1].is_major_topic | True |
| mesh[1].qualifier_name | therapeutic use |
| mesh[1].descriptor_name | Bevacizumab |
| mesh[2].qualifier_ui | Q000008 |
| mesh[2].descriptor_ui | D000068258 |
| mesh[2].is_major_topic | True |
| mesh[2].qualifier_name | administration & dosage |
| mesh[2].descriptor_name | Bevacizumab |
| mesh[3].qualifier_ui | Q000188 |
| mesh[3].descriptor_ui | D008113 |
| mesh[3].is_major_topic | True |
| mesh[3].qualifier_name | drug therapy |
| mesh[3].descriptor_name | Liver Neoplasms |
| mesh[4].qualifier_ui | Q000473 |
| mesh[4].descriptor_ui | D008113 |
| mesh[4].is_major_topic | True |
| mesh[4].qualifier_name | pathology |
| mesh[4].descriptor_name | Liver Neoplasms |
| mesh[5].qualifier_ui | Q000401 |
| mesh[5].descriptor_ui | D008113 |
| mesh[5].is_major_topic | True |
| mesh[5].qualifier_name | mortality |
| mesh[5].descriptor_name | Liver Neoplasms |
| mesh[6].qualifier_ui | Q000188 |
| mesh[6].descriptor_ui | D006528 |
| mesh[6].is_major_topic | True |
| mesh[6].qualifier_name | drug therapy |
| mesh[6].descriptor_name | Carcinoma, Hepatocellular |
| mesh[7].qualifier_ui | Q000473 |
| mesh[7].descriptor_ui | D006528 |
| mesh[7].is_major_topic | True |
| mesh[7].qualifier_name | pathology |
| mesh[7].descriptor_name | Carcinoma, Hepatocellular |
| mesh[8].qualifier_ui | Q000401 |
| mesh[8].descriptor_ui | D006528 |
| mesh[8].is_major_topic | True |
| mesh[8].qualifier_name | mortality |
| mesh[8].descriptor_name | Carcinoma, Hepatocellular |
| mesh[9].qualifier_ui | |
| mesh[9].descriptor_ui | D008297 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | |
| mesh[9].descriptor_name | Male |
| mesh[10].qualifier_ui | |
| mesh[10].descriptor_ui | D005260 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | |
| mesh[10].descriptor_name | Female |
| mesh[11].qualifier_ui | |
| mesh[11].descriptor_ui | D000368 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | |
| mesh[11].descriptor_name | Aged |
| mesh[12].qualifier_ui | Q000627 |
| mesh[12].descriptor_ui | D061067 |
| mesh[12].is_major_topic | True |
| mesh[12].qualifier_name | therapeutic use |
| mesh[12].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[13].qualifier_ui | Q000008 |
| mesh[13].descriptor_ui | D061067 |
| mesh[13].is_major_topic | True |
| mesh[13].qualifier_name | administration & dosage |
| mesh[13].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[14].qualifier_ui | |
| mesh[14].descriptor_ui | D008875 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | |
| mesh[14].descriptor_name | Middle Aged |
| mesh[15].qualifier_ui | Q000627 |
| mesh[15].descriptor_ui | D000971 |
| mesh[15].is_major_topic | True |
| mesh[15].qualifier_name | therapeutic use |
| mesh[15].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[16].qualifier_ui | |
| mesh[16].descriptor_ui | D015331 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | |
| mesh[16].descriptor_name | Cohort Studies |
| mesh[17].qualifier_ui | |
| mesh[17].descriptor_ui | D000328 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | |
| mesh[17].descriptor_name | Adult |
| mesh[18].qualifier_ui | |
| mesh[18].descriptor_ui | D006801 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | |
| mesh[18].descriptor_name | Humans |
| mesh[19].qualifier_ui | Q000627 |
| mesh[19].descriptor_ui | D000068258 |
| mesh[19].is_major_topic | True |
| mesh[19].qualifier_name | therapeutic use |
| mesh[19].descriptor_name | Bevacizumab |
| mesh[20].qualifier_ui | Q000008 |
| mesh[20].descriptor_ui | D000068258 |
| mesh[20].is_major_topic | True |
| mesh[20].qualifier_name | administration & dosage |
| mesh[20].descriptor_name | Bevacizumab |
| mesh[21].qualifier_ui | Q000188 |
| mesh[21].descriptor_ui | D008113 |
| mesh[21].is_major_topic | True |
| mesh[21].qualifier_name | drug therapy |
| mesh[21].descriptor_name | Liver Neoplasms |
| mesh[22].qualifier_ui | Q000473 |
| mesh[22].descriptor_ui | D008113 |
| mesh[22].is_major_topic | True |
| mesh[22].qualifier_name | pathology |
| mesh[22].descriptor_name | Liver Neoplasms |
| mesh[23].qualifier_ui | Q000401 |
| mesh[23].descriptor_ui | D008113 |
| mesh[23].is_major_topic | True |
| mesh[23].qualifier_name | mortality |
| mesh[23].descriptor_name | Liver Neoplasms |
| mesh[24].qualifier_ui | Q000188 |
| mesh[24].descriptor_ui | D006528 |
| mesh[24].is_major_topic | True |
| mesh[24].qualifier_name | drug therapy |
| mesh[24].descriptor_name | Carcinoma, Hepatocellular |
| mesh[25].qualifier_ui | Q000473 |
| mesh[25].descriptor_ui | D006528 |
| mesh[25].is_major_topic | True |
| mesh[25].qualifier_name | pathology |
| mesh[25].descriptor_name | Carcinoma, Hepatocellular |
| mesh[26].qualifier_ui | Q000401 |
| mesh[26].descriptor_ui | D006528 |
| mesh[26].is_major_topic | True |
| mesh[26].qualifier_name | mortality |
| mesh[26].descriptor_name | Carcinoma, Hepatocellular |
| mesh[27].qualifier_ui | |
| mesh[27].descriptor_ui | D008297 |
| mesh[27].is_major_topic | False |
| mesh[27].qualifier_name | |
| mesh[27].descriptor_name | Male |
| mesh[28].qualifier_ui | |
| mesh[28].descriptor_ui | D005260 |
| mesh[28].is_major_topic | False |
| mesh[28].qualifier_name | |
| mesh[28].descriptor_name | Female |
| mesh[29].qualifier_ui | |
| mesh[29].descriptor_ui | D000368 |
| mesh[29].is_major_topic | False |
| mesh[29].qualifier_name | |
| mesh[29].descriptor_name | Aged |
| mesh[30].qualifier_ui | Q000627 |
| mesh[30].descriptor_ui | D061067 |
| mesh[30].is_major_topic | True |
| mesh[30].qualifier_name | therapeutic use |
| mesh[30].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[31].qualifier_ui | Q000008 |
| mesh[31].descriptor_ui | D061067 |
| mesh[31].is_major_topic | True |
| mesh[31].qualifier_name | administration & dosage |
| mesh[31].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[32].qualifier_ui | |
| mesh[32].descriptor_ui | D008875 |
| mesh[32].is_major_topic | False |
| mesh[32].qualifier_name | |
| mesh[32].descriptor_name | Middle Aged |
| mesh[33].qualifier_ui | Q000627 |
| mesh[33].descriptor_ui | D000971 |
| mesh[33].is_major_topic | True |
| mesh[33].qualifier_name | therapeutic use |
| mesh[33].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[34].qualifier_ui | |
| mesh[34].descriptor_ui | D015331 |
| mesh[34].is_major_topic | False |
| mesh[34].qualifier_name | |
| mesh[34].descriptor_name | Cohort Studies |
| mesh[35].qualifier_ui | |
| mesh[35].descriptor_ui | D000328 |
| mesh[35].is_major_topic | False |
| mesh[35].qualifier_name | |
| mesh[35].descriptor_name | Adult |
| mesh[36].qualifier_ui | |
| mesh[36].descriptor_ui | D006801 |
| mesh[36].is_major_topic | False |
| mesh[36].qualifier_name | |
| mesh[36].descriptor_name | Humans |
| mesh[37].qualifier_ui | Q000627 |
| mesh[37].descriptor_ui | D000068258 |
| mesh[37].is_major_topic | True |
| mesh[37].qualifier_name | therapeutic use |
| mesh[37].descriptor_name | Bevacizumab |
| mesh[38].qualifier_ui | Q000008 |
| mesh[38].descriptor_ui | D000068258 |
| mesh[38].is_major_topic | True |
| mesh[38].qualifier_name | administration & dosage |
| mesh[38].descriptor_name | Bevacizumab |
| mesh[39].qualifier_ui | Q000188 |
| mesh[39].descriptor_ui | D008113 |
| mesh[39].is_major_topic | True |
| mesh[39].qualifier_name | drug therapy |
| mesh[39].descriptor_name | Liver Neoplasms |
| mesh[40].qualifier_ui | Q000473 |
| mesh[40].descriptor_ui | D008113 |
| mesh[40].is_major_topic | True |
| mesh[40].qualifier_name | pathology |
| mesh[40].descriptor_name | Liver Neoplasms |
| mesh[41].qualifier_ui | Q000401 |
| mesh[41].descriptor_ui | D008113 |
| mesh[41].is_major_topic | True |
| mesh[41].qualifier_name | mortality |
| mesh[41].descriptor_name | Liver Neoplasms |
| mesh[42].qualifier_ui | Q000188 |
| mesh[42].descriptor_ui | D006528 |
| mesh[42].is_major_topic | True |
| mesh[42].qualifier_name | drug therapy |
| mesh[42].descriptor_name | Carcinoma, Hepatocellular |
| mesh[43].qualifier_ui | Q000473 |
| mesh[43].descriptor_ui | D006528 |
| mesh[43].is_major_topic | True |
| mesh[43].qualifier_name | pathology |
| mesh[43].descriptor_name | Carcinoma, Hepatocellular |
| mesh[44].qualifier_ui | Q000401 |
| mesh[44].descriptor_ui | D006528 |
| mesh[44].is_major_topic | True |
| mesh[44].qualifier_name | mortality |
| mesh[44].descriptor_name | Carcinoma, Hepatocellular |
| mesh[45].qualifier_ui | |
| mesh[45].descriptor_ui | D008297 |
| mesh[45].is_major_topic | False |
| mesh[45].qualifier_name | |
| mesh[45].descriptor_name | Male |
| mesh[46].qualifier_ui | |
| mesh[46].descriptor_ui | D005260 |
| mesh[46].is_major_topic | False |
| mesh[46].qualifier_name | |
| mesh[46].descriptor_name | Female |
| mesh[47].qualifier_ui | |
| mesh[47].descriptor_ui | D000368 |
| mesh[47].is_major_topic | False |
| mesh[47].qualifier_name | |
| mesh[47].descriptor_name | Aged |
| mesh[48].qualifier_ui | Q000627 |
| mesh[48].descriptor_ui | D061067 |
| mesh[48].is_major_topic | True |
| mesh[48].qualifier_name | therapeutic use |
| mesh[48].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[49].qualifier_ui | Q000008 |
| mesh[49].descriptor_ui | D061067 |
| mesh[49].is_major_topic | True |
| mesh[49].qualifier_name | administration & dosage |
| mesh[49].descriptor_name | Antibodies, Monoclonal, Humanized |
| type | article |
| title | Atezolizumab plus bevacizumab as first-line systemic therapy for hepatocellular carcinoma: a multi-institutional cohort study |
| biblio.issue | 11 |
| biblio.volume | 29 |
| biblio.last_page | 996 |
| biblio.first_page | 986 |
| topics[0].id | https://openalex.org/T10073 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9998999834060669 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2721 |
| topics[0].subfield.display_name | Hepatology |
| topics[0].display_name | Hepatocellular Carcinoma Treatment and Prognosis |
| topics[1].id | https://openalex.org/T11364 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9991999864578247 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2746 |
| topics[1].subfield.display_name | Surgery |
| topics[1].display_name | Cholangiocarcinoma and Gallbladder Cancer Studies |
| topics[2].id | https://openalex.org/T10340 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9988999962806702 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2713 |
| topics[2].subfield.display_name | Epidemiology |
| topics[2].display_name | Hepatitis B Virus Studies |
| is_xpac | False |
| apc_list.value | 3494 |
| apc_list.currency | USD |
| apc_list.value_usd | 3494 |
| apc_paid.value | 3494 |
| apc_paid.currency | USD |
| apc_paid.value_usd | 3494 |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.8986384868621826 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C2775949291 |
| concepts[1].level | 5 |
| concepts[1].score | 0.8504148721694946 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q20707748 |
| concepts[1].display_name | Atezolizumab |
| concepts[2].id | https://openalex.org/C2777802072 |
| concepts[2].level | 3 |
| concepts[2].score | 0.7957550287246704 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q413299 |
| concepts[2].display_name | Bevacizumab |
| concepts[3].id | https://openalex.org/C126322002 |
| concepts[3].level | 1 |
| concepts[3].score | 0.76860511302948 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[3].display_name | Internal medicine |
| concepts[4].id | https://openalex.org/C2778019345 |
| concepts[4].level | 2 |
| concepts[4].score | 0.6805592179298401 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q1148337 |
| concepts[4].display_name | Hepatocellular carcinoma |
| concepts[5].id | https://openalex.org/C207103383 |
| concepts[5].level | 3 |
| concepts[5].score | 0.6084305047988892 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q3930246 |
| concepts[5].display_name | Hazard ratio |
| concepts[6].id | https://openalex.org/C50382708 |
| concepts[6].level | 2 |
| concepts[6].score | 0.5889168381690979 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q223218 |
| concepts[6].display_name | Proportional hazards model |
| concepts[7].id | https://openalex.org/C72563966 |
| concepts[7].level | 2 |
| concepts[7].score | 0.5818252563476562 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q1303415 |
| concepts[7].display_name | Cohort |
| concepts[8].id | https://openalex.org/C2781413609 |
| concepts[8].level | 2 |
| concepts[8].score | 0.5006508827209473 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q7308373 |
| concepts[8].display_name | Regimen |
| concepts[9].id | https://openalex.org/C2992208098 |
| concepts[9].level | 2 |
| concepts[9].score | 0.48731836676597595 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q1359801 |
| concepts[9].display_name | Liver function |
| concepts[10].id | https://openalex.org/C2908647359 |
| concepts[10].level | 2 |
| concepts[10].score | 0.46500882506370544 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q2625603 |
| concepts[10].display_name | Population |
| concepts[11].id | https://openalex.org/C90924648 |
| concepts[11].level | 1 |
| concepts[11].score | 0.45297425985336304 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q120569 |
| concepts[11].display_name | Gastroenterology |
| concepts[12].id | https://openalex.org/C17923572 |
| concepts[12].level | 2 |
| concepts[12].score | 0.4400913715362549 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q7250160 |
| concepts[12].display_name | Propensity score matching |
| concepts[13].id | https://openalex.org/C143998085 |
| concepts[13].level | 1 |
| concepts[13].score | 0.40987277030944824 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[13].display_name | Oncology |
| concepts[14].id | https://openalex.org/C141071460 |
| concepts[14].level | 1 |
| concepts[14].score | 0.33116981387138367 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q40821 |
| concepts[14].display_name | Surgery |
| concepts[15].id | https://openalex.org/C121608353 |
| concepts[15].level | 2 |
| concepts[15].score | 0.29161009192466736 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[15].display_name | Cancer |
| concepts[16].id | https://openalex.org/C2776694085 |
| concepts[16].level | 2 |
| concepts[16].score | 0.18892765045166016 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q974135 |
| concepts[16].display_name | Chemotherapy |
| concepts[17].id | https://openalex.org/C44249647 |
| concepts[17].level | 2 |
| concepts[17].score | 0.1096872091293335 |
| concepts[17].wikidata | https://www.wikidata.org/wiki/Q208498 |
| concepts[17].display_name | Confidence interval |
| concepts[18].id | https://openalex.org/C2777701055 |
| concepts[18].level | 3 |
| concepts[18].score | 0.0 |
| concepts[18].wikidata | https://www.wikidata.org/wiki/Q1427096 |
| concepts[18].display_name | Immunotherapy |
| concepts[19].id | https://openalex.org/C2780057760 |
| concepts[19].level | 4 |
| concepts[19].score | 0.0 |
| concepts[19].wikidata | https://www.wikidata.org/wiki/Q13896859 |
| concepts[19].display_name | Pembrolizumab |
| concepts[20].id | https://openalex.org/C99454951 |
| concepts[20].level | 1 |
| concepts[20].score | 0.0 |
| concepts[20].wikidata | https://www.wikidata.org/wiki/Q932068 |
| concepts[20].display_name | Environmental health |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.8986384868621826 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/atezolizumab |
| keywords[1].score | 0.8504148721694946 |
| keywords[1].display_name | Atezolizumab |
| keywords[2].id | https://openalex.org/keywords/bevacizumab |
| keywords[2].score | 0.7957550287246704 |
| keywords[2].display_name | Bevacizumab |
| keywords[3].id | https://openalex.org/keywords/internal-medicine |
| keywords[3].score | 0.76860511302948 |
| keywords[3].display_name | Internal medicine |
| keywords[4].id | https://openalex.org/keywords/hepatocellular-carcinoma |
| keywords[4].score | 0.6805592179298401 |
| keywords[4].display_name | Hepatocellular carcinoma |
| keywords[5].id | https://openalex.org/keywords/hazard-ratio |
| keywords[5].score | 0.6084305047988892 |
| keywords[5].display_name | Hazard ratio |
| keywords[6].id | https://openalex.org/keywords/proportional-hazards-model |
| keywords[6].score | 0.5889168381690979 |
| keywords[6].display_name | Proportional hazards model |
| keywords[7].id | https://openalex.org/keywords/cohort |
| keywords[7].score | 0.5818252563476562 |
| keywords[7].display_name | Cohort |
| keywords[8].id | https://openalex.org/keywords/regimen |
| keywords[8].score | 0.5006508827209473 |
| keywords[8].display_name | Regimen |
| keywords[9].id | https://openalex.org/keywords/liver-function |
| keywords[9].score | 0.48731836676597595 |
| keywords[9].display_name | Liver function |
| keywords[10].id | https://openalex.org/keywords/population |
| keywords[10].score | 0.46500882506370544 |
| keywords[10].display_name | Population |
| keywords[11].id | https://openalex.org/keywords/gastroenterology |
| keywords[11].score | 0.45297425985336304 |
| keywords[11].display_name | Gastroenterology |
| keywords[12].id | https://openalex.org/keywords/propensity-score-matching |
| keywords[12].score | 0.4400913715362549 |
| keywords[12].display_name | Propensity score matching |
| keywords[13].id | https://openalex.org/keywords/oncology |
| keywords[13].score | 0.40987277030944824 |
| keywords[13].display_name | Oncology |
| keywords[14].id | https://openalex.org/keywords/surgery |
| keywords[14].score | 0.33116981387138367 |
| keywords[14].display_name | Surgery |
| keywords[15].id | https://openalex.org/keywords/cancer |
| keywords[15].score | 0.29161009192466736 |
| keywords[15].display_name | Cancer |
| keywords[16].id | https://openalex.org/keywords/chemotherapy |
| keywords[16].score | 0.18892765045166016 |
| keywords[16].display_name | Chemotherapy |
| keywords[17].id | https://openalex.org/keywords/confidence-interval |
| keywords[17].score | 0.1096872091293335 |
| keywords[17].display_name | Confidence interval |
| language | en |
| locations[0].id | doi:10.1093/oncolo/oyae142 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S15523509 |
| locations[0].source.issn | 1083-7159, 1549-490X |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 1083-7159 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | The Oncologist |
| locations[0].source.host_organization | https://openalex.org/P4310316295 |
| locations[0].source.host_organization_name | AlphaMed Press |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310316295 |
| locations[0].source.host_organization_lineage_names | AlphaMed Press |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://academic.oup.com/oncolo/advance-article-pdf/doi/10.1093/oncolo/oyae142/58482539/oyae142.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | The Oncologist |
| locations[0].landing_page_url | https://doi.org/10.1093/oncolo/oyae142 |
| locations[1].id | pmid:38979643 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | The oncologist |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/38979643 |
| locations[2].id | pmh:oai:pubmedcentral.nih.gov:11546648 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S2764455111 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | PubMed Central |
| locations[2].source.host_organization | https://openalex.org/I1299303238 |
| locations[2].source.host_organization_name | National Institutes of Health |
| locations[2].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[2].license | other-oa |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | https://openalex.org/licenses/other-oa |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Oncologist |
| locations[2].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/11546648 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5017352332 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-1266-7393 |
| authorships[0].author.display_name | Michael H. Storandt |
| authorships[0].countries | US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210125099 |
| authorships[0].affiliations[0].raw_affiliation_string | Department of Internal Medicine, Mayo Clinic, Rochester, MN, United States |
| authorships[0].institutions[0].id | https://openalex.org/I4210125099 |
| authorships[0].institutions[0].ror | https://ror.org/03jp40720 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I1330342723, https://openalex.org/I4210125099 |
| authorships[0].institutions[0].country_code | US |
| authorships[0].institutions[0].display_name | Mayo Clinic in Arizona |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Michael H Storandt |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Department of Internal Medicine, Mayo Clinic, Rochester, MN, United States |
| authorships[1].author.id | https://openalex.org/A5026163032 |
| authorships[1].author.orcid | https://orcid.org/0009-0005-2390-3557 |
| authorships[1].author.display_name | Tyler Zemla |
| authorships[1].countries | US |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210146710 |
| authorships[1].affiliations[0].raw_affiliation_string | Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, United States |
| authorships[1].institutions[0].id | https://openalex.org/I4210146710 |
| authorships[1].institutions[0].ror | https://ror.org/03zzw1w08 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I1330342723, https://openalex.org/I4210146710 |
| authorships[1].institutions[0].country_code | US |
| authorships[1].institutions[0].display_name | Mayo Clinic in Florida |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Tyler J Zemla |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, United States |
| authorships[2].author.id | https://openalex.org/A5046022373 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-4532-715X |
| authorships[2].author.display_name | Kanchi Patell |
| authorships[2].countries | US |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210119077, https://openalex.org/I58956616 |
| authorships[2].affiliations[0].raw_affiliation_string | Department of Medical Oncology, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH, United States |
| authorships[2].institutions[0].id | https://openalex.org/I58956616 |
| authorships[2].institutions[0].ror | https://ror.org/051fd9666 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I58956616 |
| authorships[2].institutions[0].country_code | US |
| authorships[2].institutions[0].display_name | Case Western Reserve University |
| authorships[2].institutions[1].id | https://openalex.org/I4210119077 |
| authorships[2].institutions[1].ror | https://ror.org/02kb97560 |
| authorships[2].institutions[1].type | healthcare |
| authorships[2].institutions[1].lineage | https://openalex.org/I2799343972, https://openalex.org/I4210119077 |
| authorships[2].institutions[1].country_code | US |
| authorships[2].institutions[1].display_name | University Hospitals Seidman Cancer Center |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Kanchi Patell |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Department of Medical Oncology, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH, United States |
| authorships[3].author.id | https://openalex.org/A5070169551 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Nikolas Naleid |
| authorships[3].countries | US |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I2799343972 |
| authorships[3].affiliations[0].raw_affiliation_string | Department of Internal Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH, United States |
| authorships[3].institutions[0].id | https://openalex.org/I2799343972 |
| authorships[3].institutions[0].ror | https://ror.org/0130jk839 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I2799343972 |
| authorships[3].institutions[0].country_code | US |
| authorships[3].institutions[0].display_name | University Hospitals of Cleveland |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Nikolas Naleid |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Department of Internal Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH, United States |
| authorships[4].author.id | https://openalex.org/A5063451759 |
| authorships[4].author.orcid | https://orcid.org/0000-0001-6972-7986 |
| authorships[4].author.display_name | Jennifer Gile |
| authorships[4].countries | US |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210125099 |
| authorships[4].affiliations[0].raw_affiliation_string | Department of Medical Oncology, Mayo Clinic, Rochester, MN, United States |
| authorships[4].institutions[0].id | https://openalex.org/I4210125099 |
| authorships[4].institutions[0].ror | https://ror.org/03jp40720 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I1330342723, https://openalex.org/I4210125099 |
| authorships[4].institutions[0].country_code | US |
| authorships[4].institutions[0].display_name | Mayo Clinic in Arizona |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Jennifer J Gile |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Department of Medical Oncology, Mayo Clinic, Rochester, MN, United States |
| authorships[5].author.id | https://openalex.org/A5027558961 |
| authorships[5].author.orcid | https://orcid.org/0000-0001-7323-9213 |
| authorships[5].author.display_name | Nguyen H. Tran |
| authorships[5].countries | US |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210125099 |
| authorships[5].affiliations[0].raw_affiliation_string | Department of Medical Oncology, Mayo Clinic, Rochester, MN, United States |
| authorships[5].institutions[0].id | https://openalex.org/I4210125099 |
| authorships[5].institutions[0].ror | https://ror.org/03jp40720 |
| authorships[5].institutions[0].type | healthcare |
| authorships[5].institutions[0].lineage | https://openalex.org/I1330342723, https://openalex.org/I4210125099 |
| authorships[5].institutions[0].country_code | US |
| authorships[5].institutions[0].display_name | Mayo Clinic in Arizona |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Nguyen H Tran |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Department of Medical Oncology, Mayo Clinic, Rochester, MN, United States |
| authorships[6].author.id | https://openalex.org/A5078997248 |
| authorships[6].author.orcid | https://orcid.org/0000-0002-1582-098X |
| authorships[6].author.display_name | Sakti Chakrabarti |
| authorships[6].countries | US |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I4210119077, https://openalex.org/I58956616 |
| authorships[6].affiliations[0].raw_affiliation_string | Department of Medical Oncology, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH, United States |
| authorships[6].institutions[0].id | https://openalex.org/I58956616 |
| authorships[6].institutions[0].ror | https://ror.org/051fd9666 |
| authorships[6].institutions[0].type | education |
| authorships[6].institutions[0].lineage | https://openalex.org/I58956616 |
| authorships[6].institutions[0].country_code | US |
| authorships[6].institutions[0].display_name | Case Western Reserve University |
| authorships[6].institutions[1].id | https://openalex.org/I4210119077 |
| authorships[6].institutions[1].ror | https://ror.org/02kb97560 |
| authorships[6].institutions[1].type | healthcare |
| authorships[6].institutions[1].lineage | https://openalex.org/I2799343972, https://openalex.org/I4210119077 |
| authorships[6].institutions[1].country_code | US |
| authorships[6].institutions[1].display_name | University Hospitals Seidman Cancer Center |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Sakti Chakrabarti |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Department of Medical Oncology, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH, United States |
| authorships[7].author.id | https://openalex.org/A5101829310 |
| authorships[7].author.orcid | https://orcid.org/0000-0001-7844-5833 |
| authorships[7].author.display_name | Zhaohui Jin |
| authorships[7].countries | US |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I4210125099 |
| authorships[7].affiliations[0].raw_affiliation_string | Department of Medical Oncology, Mayo Clinic, Rochester, MN, United States |
| authorships[7].institutions[0].id | https://openalex.org/I4210125099 |
| authorships[7].institutions[0].ror | https://ror.org/03jp40720 |
| authorships[7].institutions[0].type | healthcare |
| authorships[7].institutions[0].lineage | https://openalex.org/I1330342723, https://openalex.org/I4210125099 |
| authorships[7].institutions[0].country_code | US |
| authorships[7].institutions[0].display_name | Mayo Clinic in Arizona |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Zhaohui Jin |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Department of Medical Oncology, Mayo Clinic, Rochester, MN, United States |
| authorships[8].author.id | https://openalex.org/A5018257387 |
| authorships[8].author.orcid | https://orcid.org/0000-0003-2700-2658 |
| authorships[8].author.display_name | Mitesh J. Borad |
| authorships[8].countries | US |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I4210127938 |
| authorships[8].affiliations[0].raw_affiliation_string | Department of Medical Oncology, Mayo Clinic, Phoenix, AZ, United States |
| authorships[8].institutions[0].id | https://openalex.org/I4210127938 |
| authorships[8].institutions[0].ror | https://ror.org/03660jn93 |
| authorships[8].institutions[0].type | healthcare |
| authorships[8].institutions[0].lineage | https://openalex.org/I1330342723, https://openalex.org/I4210125099, https://openalex.org/I4210127938 |
| authorships[8].institutions[0].country_code | US |
| authorships[8].institutions[0].display_name | Mayo Clinic Hospital |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Mitesh Borad |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Department of Medical Oncology, Mayo Clinic, Phoenix, AZ, United States |
| authorships[9].author.id | https://openalex.org/A5002142386 |
| authorships[9].author.orcid | https://orcid.org/0000-0002-1111-8333 |
| authorships[9].author.display_name | Amit Mahipal |
| authorships[9].countries | US |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I4210119077, https://openalex.org/I58956616 |
| authorships[9].affiliations[0].raw_affiliation_string | Department of Medical Oncology, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH, United States |
| authorships[9].institutions[0].id | https://openalex.org/I58956616 |
| authorships[9].institutions[0].ror | https://ror.org/051fd9666 |
| authorships[9].institutions[0].type | education |
| authorships[9].institutions[0].lineage | https://openalex.org/I58956616 |
| authorships[9].institutions[0].country_code | US |
| authorships[9].institutions[0].display_name | Case Western Reserve University |
| authorships[9].institutions[1].id | https://openalex.org/I4210119077 |
| authorships[9].institutions[1].ror | https://ror.org/02kb97560 |
| authorships[9].institutions[1].type | healthcare |
| authorships[9].institutions[1].lineage | https://openalex.org/I2799343972, https://openalex.org/I4210119077 |
| authorships[9].institutions[1].country_code | US |
| authorships[9].institutions[1].display_name | University Hospitals Seidman Cancer Center |
| authorships[9].author_position | last |
| authorships[9].raw_author_name | Amit Mahipal |
| authorships[9].is_corresponding | True |
| authorships[9].raw_affiliation_strings | Department of Medical Oncology, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH, United States |
| has_content.pdf | True |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://academic.oup.com/oncolo/advance-article-pdf/doi/10.1093/oncolo/oyae142/58482539/oyae142.pdf |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Atezolizumab plus bevacizumab as first-line systemic therapy for hepatocellular carcinoma: a multi-institutional cohort study |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T06:51:31.235846 |
| primary_topic.id | https://openalex.org/T10073 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9998999834060669 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2721 |
| primary_topic.subfield.display_name | Hepatology |
| primary_topic.display_name | Hepatocellular Carcinoma Treatment and Prognosis |
| related_works | https://openalex.org/W4248636606, https://openalex.org/W3024972238, https://openalex.org/W4388045576, https://openalex.org/W2186633408, https://openalex.org/W2788599721, https://openalex.org/W4393216394, https://openalex.org/W4252058598, https://openalex.org/W4389074740, https://openalex.org/W2248034498, https://openalex.org/W2361177889 |
| cited_by_count | 15 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 14 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 1 |
| locations_count | 3 |
| best_oa_location.id | doi:10.1093/oncolo/oyae142 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S15523509 |
| best_oa_location.source.issn | 1083-7159, 1549-490X |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 1083-7159 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | The Oncologist |
| best_oa_location.source.host_organization | https://openalex.org/P4310316295 |
| best_oa_location.source.host_organization_name | AlphaMed Press |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310316295 |
| best_oa_location.source.host_organization_lineage_names | AlphaMed Press |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://academic.oup.com/oncolo/advance-article-pdf/doi/10.1093/oncolo/oyae142/58482539/oyae142.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | The Oncologist |
| best_oa_location.landing_page_url | https://doi.org/10.1093/oncolo/oyae142 |
| primary_location.id | doi:10.1093/oncolo/oyae142 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S15523509 |
| primary_location.source.issn | 1083-7159, 1549-490X |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 1083-7159 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | The Oncologist |
| primary_location.source.host_organization | https://openalex.org/P4310316295 |
| primary_location.source.host_organization_name | AlphaMed Press |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310316295 |
| primary_location.source.host_organization_lineage_names | AlphaMed Press |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://academic.oup.com/oncolo/advance-article-pdf/doi/10.1093/oncolo/oyae142/58482539/oyae142.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | The Oncologist |
| primary_location.landing_page_url | https://doi.org/10.1093/oncolo/oyae142 |
| publication_date | 2024-07-09 |
| publication_year | 2024 |
| referenced_works | https://openalex.org/W4210774372, https://openalex.org/W6714246613, https://openalex.org/W2060123467, https://openalex.org/W4220885560, https://openalex.org/W2147172608, https://openalex.org/W3025022288, https://openalex.org/W2119190881, https://openalex.org/W2746030412, https://openalex.org/W2735406806, https://openalex.org/W4200388794, https://openalex.org/W2408646082, https://openalex.org/W4220787479, https://openalex.org/W4361191291, https://openalex.org/W4319872581, https://openalex.org/W4385651582, https://openalex.org/W4391090878, https://openalex.org/W4388562853, https://openalex.org/W4381597859, https://openalex.org/W2806581056, https://openalex.org/W4226288831, https://openalex.org/W4221024775, https://openalex.org/W2591717879 |
| referenced_works_count | 22 |
| abstract_inverted_index.1 | 162 |
| abstract_inverted_index.A | 28 |
| abstract_inverted_index.a | 216 |
| abstract_inverted_index.(P | 151 |
| abstract_inverted_index.10 | 106 |
| abstract_inverted_index.2. | 176 |
| abstract_inverted_index.B, | 185 |
| abstract_inverted_index.CP | 46, 180, 197 |
| abstract_inverted_index.In | 177 |
| abstract_inverted_index.OS | 129 |
| abstract_inverted_index.US | 53 |
| abstract_inverted_index.We | 35 |
| abstract_inverted_index.an | 164, 200 |
| abstract_inverted_index.as | 69 |
| abstract_inverted_index.in | 15, 23, 31, 51, 172, 244 |
| abstract_inverted_index.is | 5, 199, 231 |
| abstract_inverted_index.no | 224 |
| abstract_inverted_index.of | 8, 41, 166 |
| abstract_inverted_index.on | 45 |
| abstract_inverted_index.to | 37 |
| abstract_inverted_index.322 | 101 |
| abstract_inverted_index.4.7 | 145 |
| abstract_inverted_index.86, | 104 |
| abstract_inverted_index.9.1 | 138 |
| abstract_inverted_index.Cox | 94 |
| abstract_inverted_index.HCC | 63, 207 |
| abstract_inverted_index.age | 117 |
| abstract_inverted_index.and | 48, 76, 88, 105, 111, 124, 144, 188, 212 |
| abstract_inverted_index.for | 10, 134, 140, 147, 204, 219 |
| abstract_inverted_index.had | 108, 163 |
| abstract_inverted_index.has | 240 |
| abstract_inverted_index.mOS | 165 |
| abstract_inverted_index.the | 6, 16, 32, 39, 52, 85, 229 |
| abstract_inverted_index.was | 20, 82, 118, 131 |
| abstract_inverted_index.who | 64 |
| abstract_inverted_index.(CP) | 27 |
| abstract_inverted_index.(OS) | 81 |
| abstract_inverted_index.14.2 | 170 |
| abstract_inverted_index.2018 | 75 |
| abstract_inverted_index.21.6 | 132 |
| abstract_inverted_index.226, | 103 |
| abstract_inverted_index.34.9 | 167 |
| abstract_inverted_index.66.5 | 119 |
| abstract_inverted_index.ALBI | 49, 160, 182, 238 |
| abstract_inverted_index.CP-A | 247 |
| abstract_inverted_index.CP-C | 112 |
| abstract_inverted_index.This | 56 |
| abstract_inverted_index.care | 9 |
| abstract_inverted_index.less | 233 |
| abstract_inverted_index.only | 21 |
| abstract_inverted_index.plus | 3, 210 |
| abstract_inverted_index.than | 234 |
| abstract_inverted_index.this | 213 |
| abstract_inverted_index.tool | 203 |
| abstract_inverted_index.were | 91, 122, 126, 191 |
| abstract_inverted_index.with | 25, 62, 67, 136, 142, 149, 156, 159, 174, 194, 206, 221, 223, 236, 246 |
| abstract_inverted_index.(HCC) | 14 |
| abstract_inverted_index.(mOS) | 130 |
| abstract_inverted_index.2023. | 78 |
| abstract_inverted_index.78.6% | 121 |
| abstract_inverted_index.82.6% | 125 |
| abstract_inverted_index.Among | 100, 154 |
| abstract_inverted_index.CP-A, | 109, 137, 157 |
| abstract_inverted_index.CP-A. | 237 |
| abstract_inverted_index.CP-B, | 110 |
| abstract_inverted_index.CP-B7 | 222 |
| abstract_inverted_index.March | 74 |
| abstract_inverted_index.based | 44 |
| abstract_inverted_index.grade | 50, 161, 175 |
| abstract_inverted_index.liver | 29, 113, 248 |
| abstract_inverted_index.male, | 123 |
| abstract_inverted_index.score | 47, 198, 239 |
| abstract_inverted_index.study | 59 |
| abstract_inverted_index.these | 42 |
| abstract_inverted_index.those | 135, 141, 148, 158, 173, 235 |
| abstract_inverted_index.using | 84, 93 |
| abstract_inverted_index.value | 243 |
| abstract_inverted_index.CP-B7, | 143 |
| abstract_inverted_index.Median | 116, 128 |
| abstract_inverted_index.White. | 127 |
| abstract_inverted_index.cohort | 58 |
| abstract_inverted_index.grade, | 183 |
| abstract_inverted_index.hazard | 96 |
| abstract_inverted_index.method | 87 |
| abstract_inverted_index.months | 133, 139, 146, 168, 171 |
| abstract_inverted_index.option | 218 |
| abstract_inverted_index.safety | 226 |
| abstract_inverted_index.score, | 181 |
| abstract_inverted_index.sought | 36 |
| abstract_inverted_index.trial. | 34 |
| abstract_inverted_index.versus | 169 |
| abstract_inverted_index.viable | 217 |
| abstract_inverted_index.years, | 120 |
| abstract_inverted_index..0001). | 153 |
| abstract_inverted_index.Methods | 55 |
| abstract_inverted_index.Overall | 79 |
| abstract_inverted_index.Results | 99 |
| abstract_inverted_index.benefit | 230 |
| abstract_inverted_index.between | 73 |
| abstract_inverted_index.method. | 98 |
| abstract_inverted_index.regimen | 214 |
| abstract_inverted_index.remains | 215 |
| abstract_inverted_index.status, | 187 |
| abstract_inverted_index.therapy | 72 |
| abstract_inverted_index.&lt; | 152 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.November | 77 |
| abstract_inverted_index.advanced | 11 |
| abstract_inverted_index.although | 19, 228 |
| abstract_inverted_index.analyses | 90 |
| abstract_inverted_index.concern, | 227 |
| abstract_inverted_index.function | 30 |
| abstract_inverted_index.included | 60 |
| abstract_inverted_index.invasion | 190 |
| abstract_inverted_index.outcomes | 40 |
| abstract_inverted_index.patients | 24, 43, 61, 107, 155, 205, 220, 245 |
| abstract_inverted_index.received | 65 |
| abstract_inverted_index.setting, | 18 |
| abstract_inverted_index.standard | 7 |
| abstract_inverted_index.survival | 80 |
| abstract_inverted_index.systemic | 71 |
| abstract_inverted_index.CP-B8-C12 | 150 |
| abstract_inverted_index.analyses, | 179 |
| abstract_inverted_index.carcinoma | 13 |
| abstract_inverted_index.determine | 38 |
| abstract_inverted_index.evaluated | 22 |
| abstract_inverted_index.function, | 114 |
| abstract_inverted_index.function. | 249 |
| abstract_inverted_index.hepatitis | 184 |
| abstract_inverted_index.important | 201 |
| abstract_inverted_index.patients, | 102 |
| abstract_inverted_index.performed | 92 |
| abstract_inverted_index.receiving | 208 |
| abstract_inverted_index.survival. | 195 |
| abstract_inverted_index.Background | 1 |
| abstract_inverted_index.Child-Pugh | 26 |
| abstract_inverted_index.IMbrave150 | 33 |
| abstract_inverted_index.additional | 225 |
| abstract_inverted_index.associated | 193 |
| abstract_inverted_index.determined | 83 |
| abstract_inverted_index.first-line | 17, 70 |
| abstract_inverted_index.predictive | 242 |
| abstract_inverted_index.prognostic | 202 |
| abstract_inverted_index.regression | 97 |
| abstract_inverted_index.Conclusions | 196 |
| abstract_inverted_index.bevacizumab | 4, 68 |
| abstract_inverted_index.independent | 241 |
| abstract_inverted_index.multicenter | 57 |
| abstract_inverted_index.performance | 186 |
| abstract_inverted_index.population. | 54 |
| abstract_inverted_index.Atezolizumab | 2 |
| abstract_inverted_index.Kaplan-Meier | 86 |
| abstract_inverted_index.atezolizumab | 66, 209 |
| abstract_inverted_index.bevacizumab, | 211 |
| abstract_inverted_index.multivariate | 89, 178 |
| abstract_inverted_index.proportional | 95 |
| abstract_inverted_index.macrovascular | 189 |
| abstract_inverted_index.respectively. | 115 |
| abstract_inverted_index.significantly | 192, 232 |
| abstract_inverted_index.hepatocellular | 12 |
| cited_by_percentile_year.max | 100 |
| cited_by_percentile_year.min | 90 |
| corresponding_author_ids | https://openalex.org/A5002142386 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 10 |
| corresponding_institution_ids | https://openalex.org/I4210119077, https://openalex.org/I58956616 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8299999833106995 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.98028371 |
| citation_normalized_percentile.is_in_top_1_percent | True |
| citation_normalized_percentile.is_in_top_10_percent | True |